Health insurers promise to improve coverage reviews that prompt delays and complaints

Novo Nordisk, the company behind the popular weight-loss drug Wegovy, just pulled the plug on its partnership with telehealth provider Hims & Hers. The reason? Allegations that Hims was playing fast and loose with compounding (mixing their own versions of the drug) and using shady marketing tactics. The news hit Hims & Hers hard—their stock plummeted over 30% in response.

Editor’s Note: This isn’t just corporate drama—it’s a big deal because Wegovy is one of the hottest drugs right now, and Novo Nordisk clearly doesn’t want its reputation tarnished by sketchy practices. For Hims & Hers, losing this deal is a major blow, especially since telehealth companies rely on credibility to keep customers trusting their prescriptions. It also raises questions about how tightly controlled these high-demand drugs should be as more players jump into the market.

A new monthly weight loss drug developed by Amgen has shown promising results in a phase 2 trial, with participants losing roughly 20% of their body weight. If further testing confirms its safety and effectiveness, this could be a game-changer for people struggling with obesity—offering a simpler, less frequent dosing option compared to current weekly injections.

Editor’s Note: Obesity is a massive global health challenge, and existing treatments often require frequent injections or lifestyle changes that are hard to sustain. A monthly drug could make weight loss more accessible and manageable for millions. While it’s still early days (phase 2 trials are mid-stage), this could signal a major shift in how we approach weight management. Keep an eye on this one.

Star Pacers guard Tyrese Haliburton suffered a devastating injury during the NBA Finals' decisive Game 7, reportedly tearing his right Achilles tendon in the team's loss to the Celtics. This type of injury typically requires a long and challenging recovery, casting doubt on his availability for next season.

Editor’s Note: Haliburton's injury is a massive blow—not just for the Pacers, but for the league. He’s one of the NBA’s brightest young talents, and Achilles tears have derailed careers before. Fans will be holding their breath to see how he bounces back.

Gen Z is shaking up traditional views on sex—but not in the way you might think. Journalist Carter Sherman explores how younger adults are having less sex than older generations did at their age, linking the trend to everything from pandemic isolation to today’s charged political and social landscape. Her book, The Second Coming, digs into why norms are shifting and what it says about this generation’s relationship with intimacy.

Editor’s Note: Sex isn’t just about personal choices—it’s a mirror of broader cultural shifts. If Gen Z is pulling back from physical intimacy, it hints at deeper anxieties, from privacy concerns to economic instability. Understanding this trend helps decode how younger people navigate love, connection, and even their mental health in a rapidly changing world.

This piece rounds up the latest chatter in the health care sector, spotlighting key players like Novo Nordisk (think weight-loss drugs), Thailand’s Bumrungrad Hospital, and investment firm Riverstone Holdings. It’s a quick hit of market-moving insights—no deep dives, just the highlights you’d catch in a finance-savvy coffee break.

Editor’s Note: If you’re tracking how health care companies are performing financially—whether it’s buzzy drugmakers or international hospital chains—this snapshot gives you the pulse without wading through earnings reports. It’s like a cheat sheet for investors or anyone curious about where the money’s flowing in medicine.